Home Newsfeeds ORIC Pharmaceuticals Expects Initial 1b Data For 3 Ongoing Trials In H1 2023

News

ORIC Pharmaceuticals Expects Initial 1b Data For 3 Ongoing Trials In H1 2023

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Development candidate

byBenzinga Newsdesk

January 9, 2023

1 minute read

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

Development candidate selected for PLK4 synthetic lethal breast cancer program

Cash and investments of $228 million expected to fund operating plan into first half of 2025

News

Why Charles Schwab (SCHW) Shares Are Trading Higher

By Henry Khederian

June 29, 3:28 PM

Charles Schwab Corporation Common Stock (NYSE: SCHW) shares are trading higher by 2.53% to $57.19 Thursday afternoon.

SCHW

Cantor Fitzgerald Maintains Neutral on TerrAscend, Lowers Price Target to $2.15

By Benzinga Newsdesk

October 28, 6:03 AM

Cantor Fitzgerald analyst Pablo Zuanic maintains TerrAscend (OTC:TRSSF) with a Neutral and lowers the price target from $2.85 to $2.15.

TRSSF

Maxeon Solar Technologies Loses 50% Value In One Session After Q1 Earnings – Here’s Why

By Anusuya Lahiri

May 30, 10:54 AM

Maxeon Solar Technologies (NASDAQ: MAXN) reported Q1 revenue of $187.46M, missing estimates. EPS loss of $(1.59) also missed. Quarterly shipments declined 37%. Maxeon projects lower Q2 and FY24 revenue and significant investment from shareholder.

MAXN